<DOC>
	<DOCNO>NCT01732770</DOCNO>
	<brief_summary>This study compare effectiveness denosumab treatment every 6 month yearly zoledronic acid treatment bone mineral density ( BMD ) various skeletal site .</brief_summary>
	<brief_title>Safety Efficacy Study Evaluate Denosumab Compared With Zoledronic Acid Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Ambulatory postmenopausal woman . Age 55 year old Subject provide informed consent prior study specific procedure Received oral bisphosphonate therapy osteoporosis least 2 year prior screen visit Screening BMD ( g/cm² ) value lumbar spine , total hip femoral neck value equal less list protocol . At least 2 lumbar vertebra one hip must evaluable dual energy xray absorptiometry ( DXA ) screen visit Received osteoporosis treatment bone active treatment Evidence history follow : hyperthyroidism ( stable antithyroid therapy allow ) hypothyroidism ( stable thyroid replacement therapy allow ) hypo hyperparathyroidism hypo hypercalcemia base central laboratory reference range Recent tooth extraction ( within 6 month screen visit ) Paget disease bone ( subject report chart review ) bone disease affect bone metabolism ( eg , osteopetrosis , osteogenesis imperfecta ) ( chart review ) Abnormalities follow per central laboratory reference range : vitamin D deficiency ( 25 [ OH ] vitamin D level &lt; 20 ng/mL ) , repletion allow subject may rescreened hypercalcemia elevate transaminase ≥ 2.0 x upper limit normal ( ULN ) History solid organ bone marrow transplant Malignancy ( except nonmelanoma skin cancer , cervical breast ductal carcinoma situ ) within last 5 year Known intolerance calcium vitamin D supplement Selfreported alcohol drug abuse within 12 month prior screen Currently receive treatment another investigational device drug study , less 30 day since end treatment another investigational device drug study ( ) History evidence clinically significant disorder , condition disease opinion Investigator Amgen physician , consult , would pose risk subject safety interfere study evaluation , procedure completion</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>